GHRL and myocardial infarction: Hexarelin is a stable synthetic GHS peptide analog of ghrelin that has been shown to have a wide range of cytoprotective and cardioprotective actions in vitro and in vivo, such as amelioration of LV dysfunction and remodeling in the setting of pressure overload and myocardial infarction (Berti et al., 1998; Filigheddu et al., 2001; Mao et al., 2013a, 2014a,b; Mcdonald et al., 2020).